Founded in 2002, Domainex specialises in the provision of protein science and medicinal chemistry services to both large pharmaceutical and biotechnology companies and to academic research groups.
The company is also developing a pipeline of pre-clinical drugs and targets.
De Facto MD Mike Wort said of the win: ‘Domainex's core technologies are cutting edge and we want to implement a comms programme to raise the company's profile.'
He added: ‘We also aim to make target audiences fully aware of its specialist capabilities and its development of novel technologies that are set to make a truly transforming mark on the drug discovery sector.'
Domainex recently announced an asthma treatment collaboration with St. George's Hospital Medical School and the University of Manchester.